|
1.
|
Chalbos D, Vignon F, Keydar I and
Rochefort H: Estrogens stimulate cell proliferation and induce
secretory proteins in a human breast cancer cell line (T47D). J
Clin Endocrinol Metab. 55:276–283. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Russo J and Russo IH: The role of estrogen
in the initiation of breast cancer. J Steroid Biochem Mol Biol.
102:89–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Beatson G: On the treatment of inoperable
cases of carcinoma of the mamma: suggestions for a new method of
treatment, with illustrative cases. Lancet. 147:101–107. 1986.
|
|
4.
|
Smith IE and Dowsett M: Aromatase
inhibitors in breast cancer. N Engl J Med. 348:2431–2442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Osborne CK: Tamoxifen in the treatment of
breast cancer. N Engl J Med. 339:1609–1618. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Allred DC, Mohsin SK and Fuqua SA:
Histological and biological evolution of human premalignant breast
disease. Endocr Relat Cancer. 8:47–61. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Elledge RM and Fuqua SAW: Estrogen and
progesterone receptors. Diseases of the Breast. Harris JR, Lippman
ME, Morrow M, et al: Lippincott, Williams & Wilkins;
Philadelphia: pp. 471–488. 2000
|
|
8.
|
Hopp TA, Weiss HL, Parra IS, Cui Y,
Osborne CK and Fuqua SA: Low levels of estrogen receptor β protein
predict resistance to tamoxifen therapy in breast cancer. Clin
Cancer Res. 10:7490–7499. 2004.
|
|
9.
|
Pike MC, Spicer DV, Dahmoush L and Press
MF: Estrogens, progestins, normal breast cell proliferation, and
breast cancer risk. Epidemiol Rev. 15:17–35. 1993.PubMed/NCBI
|
|
10.
|
McGuire WL, Chamness GC and Fuqua SA:
Estrogen receptor variants in clinical breast cancer. Mol
Endocrinol. 5:1571–1577. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Herynk MH, Parra I, Cui Y, Beyer A, Wu MF,
Hilsenbeck SG and Fuqua SA: Association between the estrogen
receptor α A908G mutation and outcomes in invasive breast cancer.
Clin Cancer Res. 13:3235–3243. 2007.
|
|
12.
|
Fuqua SA, Wiltschke C, Zhang QX, Borg A,
Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S,
O'Connell P and Allred DC: A hypersensitive estrogen receptor-α
mutation in premalignant breast lesions. Cancer Res. 60:4026–4029.
2000.
|
|
13.
|
Tebbit CL, Bentley RC, Olson JA Jr and
Marks JR: Estrogen receptor α (ESR1) mutant A908G is not a common
feature in benign and malignant proliferations of the breast. Genes
Chromosomes Cancer. 40:51–54. 2004.
|
|
14.
|
Tokunaga E, Kimura Y and Maehara Y: No
hypersensitive estrogen receptor-α mutation (K303R) in Japanese
breast carcinomas. Breast Cancer Res Treat. 84:289–292. 2004.
|
|
15.
|
Davies MP, O'Neill PA, Innes H and Sibson
DR: Hypersensitive K303R oestrogen receptor-α variant not found in
invasive carcinomas. Breast Cancer Res. 7:R113–R118. 2005.
|
|
16.
|
Zhang Z, Yamashita H, Toyama T, Omoto Y,
Sugiura H, Hara Y, Haruki N, Kobayashi S and Iwase H: Estrogen
receptor α mutation (A-to-G transition at nucleotide 908) is not
found in different types of breast lesions from Japanese women.
Breast Cancer. 10:70–73. 2003.
|
|
17.
|
Conway K, Parrish E, Edmiston SN, Tolbert
D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B and Millikan RC:
The estrogen receptor-α A908G (K303R) mutation occurs at a low
frequency in invasive breast tumors: results from a
population-based study. Breast Cancer Res. 7:R871–R880. 2005.
|
|
18.
|
Cui Y, Zhang M, Pestell R, Curran EM,
Welshons WV and Fuqua SA: Phosphorylation of estrogen receptor α
blocks its acetylation and regulates estrogen sensitivity. Cancer
Res. 64:9199–9208. 2004.
|
|
19.
|
Giordano C, Cui Y, Barone I, Ando S,
Mancini MA, Berno V and Fuqua SA: Growth factor-induced resistance
to tamoxifen is associated with a mutation of estrogen receptor
alpha and its phosphorylation at serine 305. Breast Cancer Res
Treat. 119:71–85. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
|
|
21.
|
Barone I, Cui Y, Herynk MH,
Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Andò S and
Fuqua SA: Expression of the K303R estrogen receptor-α breast cancer
mutation induces resistance to an aromatase inhibitor via addiction
to the PI3K/Akt kinase pathway. Cancer Res. 69:4724–4732. 2009.
|
|
22.
|
Conway K, Parrish E, Edmiston SN, Tolbert
D and Tse CK: Risk factors for breast cancer characterized by the
estrogen receptor alpha A908G (K303R) mutation. Breast Cancer Res.
9:R362007. View
Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Li CI, Malone KE, Porter PL, Weiss NS and
Tang MT: Reproductive and anthropometric factors in relation to the
risk of lobular and ductal breast carcinoma among women 65–79 years
of age. Int J Cancer. 107:647–651. 2003.PubMed/NCBI
|
